A Phase 3 interventional study of Bupropion and Zonisamide in Smoking Cessation, sponsored by Rose Research Center, LLC. Completed at 2 sites in United States. Open to participants aged 21 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-06.
Sponsored by Rose Research Center, LLC · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 48 studies testing bupropion in Smoking Cessation — 4 open to participants now, 4 under way, 2 of them phase 3. Bupropion · Smoking Cessation.
Among the 48 studies testing bupropion in Smoking Cessation, this one is the 24th largest by enrollment, is one of 3 that started in 2021, is one of 14 in phase 3, and was the 42nd registered.
1,582 studies on the registry are indexed under Smoking Cessation; 198 are open to participants now.
Browse Smoking Cessation studies →4 of the 48 studies testing bupropion in Smoking Cessation are open now, in 1 country. Recruiting first, the newest first:
Axsome Therapeutics, Inc. · Sites in United States
Ages 18–65
University of Kansas Medical Center · Sites in United States
Ages 18+ · Healthy volunteers
Medical University of South Carolina · Sites in United States
Ages 18–65
Medical University of South Carolina · Sites in United States
Ages 18–65
By country, each count listing its studies:
Bupropion: first FDA approval 1985 (WELLBUTRIN), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 137 Smoking Cessation studies recruiting now, 93 (68%) set no upper age limit and 37 (27%) stop at 75 or younger; 6 take children under 18; 41 take healthy volunteers.
This study: 21 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
48 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 11 · Phase 3 15 · Phase 4 17
First in 1998; this study’s year is marked. 3 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 180 is close to the median of 164 across 1,424 interventional studies indexed under Smoking Cessation.
Median enrollment 162 across the 48 interventional studies. Of the 42 that completed or were terminated, 22 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 48 have an industry lead sponsor. The 10 most frequent:
Rose Research Center, LLC is the lead sponsor of 13 studies on the registry; none are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 3 (38%) have results posted.
10 studies in Smoking Cessation by Rose Research Center, LLC: none open now, none under way, none of them phase 3. Of 9 finished, 4 (44%) have results posted.
Among the 10 studies in Smoking Cessation by Rose Research Center, LLC, this one has the largest enrollment, is one of 2 that started in 2021, is one of 4 in phase 3, and was the 6th registered.
Rose Research Center, LLC’s Smoking Cessation studies by the year they started, since 2019.
1 of the studies testing bupropion in Smoking Cessation that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05732272Phase 3University of Kansas Medical CenterImproving Smoking Abstinence Outcomes in the African American Community Through Extended Treatment | 2027-01-31 |
Add it to your calendar (.ics) → With an account.
Among the 48 studies testing bupropion in Smoking Cessation, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Rose Research Center, LLC’s 10 in Smoking Cessation:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This three-group randomized double-blind placebo-controlled trial (N=180) will evaluate the impact of combination zonisamide and bupropion on the process of switching from combustible cigarettes (CCs) to an e-cigarette. There will be a data collection period of at least five days to obtain baseline information on the use of combustible cigarettes. All participants enrolled in the study will receive a JUUL e-cigarette at Visit 2 for ad libitum use. After the first week of e-cigarette use (at Visit 3), participants will be given bupropion (150 mg each morning for days 1-3, then 300 mg daily) with either zonisamide (100 mg daily) or placebo (group 1 and group 2 respectively), or placebo for both medications (group 3) in addition to continued use of the e-cigarette. At each visit, participants will receive enough study drugs (or placebos) and e-cigarettes to last until their next study visit. The combination of zonisamide and bupropion use will continue until Visit 6 (7 weeks of treatment), and e-cigarette use will continue until the end of treatment (Visit 7).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Has used any of these products in the past 30 days:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
After the first week of e-cigarette use (JUUL), participants will be given bupropion (150 mg each morning for days 1-3, then 300 mg daily) with zonisamide (100 mg daily). The combination of zonisamide and bupropion use will continue for 7 weeks of treatment, and e-cigarette use will continue until the end of the study (an additional 4 weeks).
Drug: Bupropion · Drug: Zonisamide · Other: E-cigarette
After the first week of e-cigarette use (JUUL), participants will be given bupropion (150 mg each morning for days 1-3, then 300 mg daily) with placebo zonisamide. The combination of placebo and bupropion use will continue for 7 weeks of treatment, and e-cigarette use will continue until the end of the study (an additional 4 weeks).
Drug: Bupropion · Drug: Placebo zonisamide · Other: E-cigarette
After the first week of e-cigarette use (JUUL), participants will be given placebo bupropion with placebo zonisamide. The combination of these placebos will continue for 7 weeks of treatment, and e-cigarette use will continue until the end of the study (an additional 4 weeks).
Drug: Placebo bupropion · Drug: Placebo zonisamide · Other: E-cigarette
Extended-release bupropion dosing (150 mg each morning days 1-3, then 300 mg/daily) for the remainder of the 7 weeks.
Also known as: Wellbutrin, Zyban
Zonisamide (100 mg/daily) for 7 weeks.
Also known as: zonegran
Placebo bupropion for 7 weeks.
Placebo zonisamide for 7 weeks.
e-cigarette for ad libitum use for two weeks prior to complete switch day and for an additional 10 weeks.
Also known as: JUUL
Complete Switching From Combustible Cigarettes to JUUL e-cigarette as measured by Exhaled carbon monoxide (CO)
Exhaled carbon monoxide (CO) \< 5 ppm at the end of drug treatment
Time frame: After 8 weeks
Complete Switching From Combustible Cigarettes to JUUL e-cigarette as measured by change in Total urinary 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL)
Total urinary 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL)
Time frame: Baseline, Week 8, Week 12
Complete Switching From Combustible Cigarettes to JUUL e-cigarette as measured by change in self-report of daily cigarette and e-cigarette use
Self-report of daily cigarette and e-cigarette use
Time frame: Daily from Week 2 to Week 12
Change in Smoking withdrawal symptoms
Smoking withdrawal symptoms will be collected using a questionnaire developed by Drs. Shiffman and Jarvik (1976), which assesses craving for cigarettes, negative mood, arousal, missing the habit of smoking, changes in appetite and somatic symptoms and a seven-point scale (from 1-Not at All to 7-Extremely). Higher scores indicate more withdrawal symptoms.
Time frame: Baseline, Week 1, Week 2, Week 4, Week 8, Week 12
Change in Rewarding and aversive effects of smoking and e-cigarette use
The mCEQ-E will be utilized to assess the degree to which participants experience the reinforcing of smoking, providing five subscale scores: smoking satisfaction (satisfying, tastes good,enjoy smoking), psychological rewards (calms down, more awake, less irritable, helps concentrate, reduces hunger), aversion (dizziness, nauseated), enjoyment of respiratory tract sensations (single-item assessment), craving reduction (single-item assessment). Participants will be asked to assess the 12 items of the questionnaire on a 7-point scale, ranging from "not at all" to "extremely". These 12 items will be asked for the "first cigarette smoked", "cigarette immediately after a meal", and "all other cigarettes." The e-cigarette version of this questionnaire (mECEQ-E) will also be used.
Time frame: Baseline, Week 1, Week 2, Week 4, Week 8, Week 12
Tolerability of study drugs as measured by frequency of drug termination or drug non-adherence
The frequency of drug termination or non-adherence prior to Week 8 will be tabulated for each condition. Adverse effects will also be tabulated for each condition, including the following adverse effects of special interest (AESIs): insomnia, agitation, dry mouth, somnolence, headache, nausea, constipation, diarrhea, dizziness or loss of appetite.
Time frame: Baseline, Week 1, Week 2, Week 4, Week 8
Seven-day point abstinence at 6 months post-switch
Seven-day point abstinence at 6 months post-switch will be assessed by self-report and confirmed by exhaled carbon monoxide (CO) \< 5 ppm.
Time frame: 6 Months post Switch Day
Plan to share: No
Ran from Dec 2021 to primary completion in Jun 2025, 42 months.
Of 31 phase 3 interventional studies under Smoking Cessation, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 60. This study's 42 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Bupropion · Zonisamide
Rose Research Center, LLC